Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 4/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746101 | 1.00 | CA2 (0.42) | CA2CA4TDP1SMN1; SMN2MME | |
| SCHEMBL13654785 | 0.88 | CA2 (0.51) | CA2CA4SMN1; SMN2MMEFNTA | |
| SCHEMBL21954042 | 0.82 | GABRR1 (0.33) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL13020988 | 0.82 | ALOX15 (0.34) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL2918805 | 0.82 | ECE1 (0.42) | CA2FOLH1MAPT | |
| SCHEMBL8028150 | 0.82 | ECE1 (0.42) | CA2FOLH1MAPT | |
| SCHEMBL28337307 | 0.82 | KDM4E (0.38) | TDP1SMN1; SMN2MMEFNTAFNTB | |
| SCHEMBL14989156 | 0.81 | EPHX2 (0.37) | CA2CA4MAPT | |
| SCHEMBL9021257 | 0.80 | SLC22A6 (0.32) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL5088899 | 0.79 | CA2 (0.41) | CA2CA4TDP1SMN1; SMN2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105523833-A | Special slow release water-soluble fertilizer for cotton, and preparation method thereof | CHENGDU NEW KELI CHEM SCI CO | 2016-04-27 | — | — | CN | claimed |
| CN-105503404-A | Special organic water-soluble fertilizer for tea trees and preparation method of organic water-soluble fertilizer | CHENGDU NEW KELI CHEM SCI CO | 2016-04-20 | — | — | CN | claimed |
| CN-104671991-A | Special slow-released water-soluble fertilizer for american ginseng and preparation method thereof | CHENGDU NEW KELI CHEM SCI CO | 2015-06-03 | — | — | CN | claimed |
| CN-104591879-A | Special controlled-release water soluble fertilizer for grapes and preparation method thereof | CHENGDU NEW KELI CHEM SCI CO | 2015-05-06 | — | — | CN | claimed |
| CN-104557298-A | Special sustained-release water-soluble fertilizer for potatoes and preparation method of fertilizer | CHENGDU NEW KELI CHEM SCI CO | 2015-04-29 | — | — | CN | claimed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023083291-A1 | DERIVATIVE OF ASPARTIC ACID AND USE THEREOF IN TREATMENT OF METABOLIC DISEASES SUCH AS HEPATIC FIBROSIS AND NON-ALCOHOLIC HEPATITIS | 深圳利沃生物医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-106396869-A | Yield-increase and quality-improvement water soluble fertilizer used for grapes | 安徽省司尔特肥业股份有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-105523833-A | Special slow release water-soluble fertilizer for cotton, and preparation method thereof | CHENGDU NEW KELI CHEM SCI CO | 2016-04-27 | — | — | CN | disclosed |
| CN-105503404-A | Special organic water-soluble fertilizer for tea trees and preparation method of organic water-soluble fertilizer | CHENGDU NEW KELI CHEM SCI CO | 2016-04-20 | — | — | CN | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| EP-0093128-B1 | PROCESS FOR PREPARING OF METHYL ESTER OF ALPHA-ASPARTYL PHENYL ALANINE | LABORATOIRES FOURNIER S.A. (FR) | 1985-08-21 | — | — | EP | disclosed |
| EP-0055612-B1 | RECOVERY OF L-PHENYLALANINE AND L-ASPARTIC ACID DURING PREPARATION OF ALPHA-L-ASPARTYL-L-PHENYLALANINE METHYL ESTER | MONSANTO COMPANY (US) | 1984-08-08 | — | — | EP | disclosed |
| EP-0093128-A1 | PROCESS FOR PREPARING OF METHYL ESTER OF ALPHA-ASPARTYL PHENYL ALANINE. | FOURNIER LAB SA (FR) | 1983-11-09 | — | — | EP | disclosed |
| WO-1983001619-A1 | METHOD FOR THE PREPARATION OF METHYL ESTER OF 'alpha'-ASPARTYL PHENYLALANINE | GOURBAULT, MAURICE, JEAN | 1983-05-11 | — | — | WO | disclosed |
| US-4348317-A | Recovery of L-phenylalanine and L-aspartic acid during preparation of α-L-aspartyl-L-phenylalanine methyl ester | MONSANTO COMPANY (US) | 1982-09-07 | — | — | US | disclosed |
| EP-0055612-A1 | Recovery of L-phenylalanine and L-aspartic acid during preparation of alpha-L-aspartyl-L-phenylalanine methyl ester | MONSANTO COMPANY (US) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | CA2 2121/4885CA4 1466/4885TDP1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.